The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial
Services
Services
Date issued
2014Journal title
CLINICAL CANCER RESEARCH
Type of content
Artigo
